More important, by integrating artificial intelligence–assisted (AI-assisted) drug discovery, we identified a FASN inhibitor, FASstatin, that can promote TRIM56-mediated FASN protein degradation and suppress NAFLD in mice with a good efficacy and safety profile. Here, FASN is linked to metabolic dysfunction-associated steatotic liver disease.